Dr. Jingtao Luo 骆惊涛
Chief Physician, Associate Professor
Department of Head and Neck Oncology (Thyroid, Maxillofacial, and Otolaryngology), Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Thyroid tumors (open and endoscopic surgery, including da Vinci robotic techniques), head and neck cancers (oral, pharyngeal, laryngeal), salivary gland tumors, and functional reconstruction.
Dr. Luo is a Chief Physician, Associate Professor, and MD Anderson Cancer Center postdoctoral fellow. As a clinical PI at Tianjin Medical University Cancer Institute & Hospital, Dr. Luo holds two National Natural Science Foundation grants. Research includes over 20 publications in journals such as Oncogene and Cancer Letters, plus two patents. Honors include Tianjin High-Level Health Talent.
Professional roles
- Member, Head and Neck Oncology Professional Committee, China Medicine Education Association
- Member, Head and Neck Oncology Professional Committee, Tianjin Anti-Cancer Association
- Member, Thyroid Minimally Invasive Cosmetic Surgery Society, Cross-Strait Medical and Health Exchange Association
- Review Expert, National Natural Science Foundation of China
Name order: in Chinese the family name comes first (Luo Jingtao). Papers usually list the name as Jingtao Luo or Luo J.
Selected publications
23 papers on PubMed matched by name and affiliation; 15 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Cancer, 2026 (senior author): SLC3A2 identified as a new therapeutic target for head and neck squamous cell carcinoma. PubMed 42995537
- Ann Surg Oncol, 2026 (senior author): ASO Visual Abstract: Association of Preoperative Ultrasound-Measured Tumor Proximity to Trachea and Posterior Capsule with Tracheal and RLN Invasion in Papillary Thyroid Microcarcinoma. PubMed 42479356
- Ann Surg Oncol, 2026 (senior author): Association of Preoperative Ultrasound-Measured Tumor Proximity to Trachea and Posterior Capsule with Tracheal and RLN Invasion in Papillary Thyroid Microcarcinoma. PubMed 42348150
- Nat Commun, 2025 (senior author): CAV2-expressing nerves induce metabolic switch toward mitochondrial oxidative phosphorylation to promote cancer stemness. PubMed 41330921
- Mol Carcinog, 2024 (senior author): Neuronal CFL1 upregulation in head and neck squamous cell carcinoma enhances tumor-nerve crosstalk and promotes tumor growth. PubMed 38353363
- Mol Cell Biochem, 2023 (first author): CircMAT2B facilitates the progression of head and neck squamous cell carcinoma via sponging miR-491-5p to trigger ASCT2-mediated glutaminolysis. PubMed 36219356
- Biochem Genet, 2023 (first author): A Circular RNA, hsa_circ_0018180 (circPARD3), Triggers Glycolysis and Promotes Malignancy of Head and Neck Squamous Cell Carcinoma Through the miR-5194/ENO1 Axis. PubMed 35900705
- Cancers (Basel), 2022 (first author): Anti-Anaplastic Thyroid Cancer (ATC) Effects and Mechanisms of PLX3397 (Pexidartinib), a Multi-Targeted Tyrosine Kinase Inhibitor (TKI). PubMed 36612171
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion